Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: A phase II study

Annals of Oncology

Volumn 23, Issue 10, 2012, Pages 2599-2605

  Collea, R P ^a,b   Kruter, F W ^a,c   Cantrell, J E ^a,d   George, T K ^a,e   Kruger, S ^a,f   Favret, A M ^a,g   Lindquist, D L ^a,h   Melnyk, A M ^a,e   Pluenneke, R E ^a,i   Shao, S H ^a,j   Crockett, M W ^a   Asmar, L ^a   O'shaughnessy, J ^a,k  

^a US Oncology Research   (United States)

^b New York Oncology Hematology Center   (United States)

^c Alliance Hematology Oncology PA   (United States)

^d Birmingham Hematology Oncology   (United States)

^e TEXAS ONCOLOGY   (United States)

^f Virginia Oncology Associates   (United States)

^g Northern Virginia Hematology Oncology   (United States)

^h Arizona Oncology ^*  (United States)

ⁱ Kansas City Cancer Center   (United States)

^j Northwest Cancer Specialists   (United States)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Anthracycline; Cardiotoxicity; Community based; Multicenter; Platinum

Indexed keywords

CARBOPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; INFUSION RELATED REACTION; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DOXORUBICIN; HUMANS; NEOPLASM METASTASIS; POLYETHYLENE GLYCOLS;

EID: 84867135890     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds052     Document Type: Article

References (35)

1. Christodoulou C, Kostopoulos I, Kalofonos HP et al. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology 2009; 76: 275-285.
2. Adamo V, Lorusso V, Rossello R et al. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. Br J Cancer 2008; 98: 1916-1921.
3. Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006; 24: 2773-2778.
4. Wolff AC, Wang M, Li H et al. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. Breast Cancer Res Treat 2010; 121: 111-120.
5. Trudeau ME, Clemons MJ, Provencher L et al. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. J Clin Oncol 2009; 27: 5906-5910.
6. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-422.
7. Bonnefoi H, Smith IE, O'Brien ME et al. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Br J Cancer 1996; 73: 391-396.
8. Vorobiof DA, Rapoport B, Slabber C et al. Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer. Proc Am Soc Clin Oncol 2004; 22: 5091a. (Abstr).
9. Alberts DS, Liu PY, Wilczynski SP et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008; 108: 90-94.
10. Chia SK, Clemons M, Martin LA et al. A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004; 22: 630a. (Abstr).
11. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-2671.
12. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev3.pdf#search=" ctcae%20v%203.0" (12 June 2010, date last accessed).
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JASA 1958; 53: 457-458.
15. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist 2003; 8: 3-9.
16. Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-1047.
17. Ranson MR, Carmichael J, O'Byrne K et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185-3191.
18. Lyass O, Uziely B, Heching E et al. Doxil in metastatic breast cancer after prior chemotherapy: therapeutic results in two consecutive studies. Proc Am Soc Clin Oncol 1998; 17: 597A.
19. Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients-results of a phase II study. Cancer Chemother Pharmacol 1991; 27: 409-412.
20. Martin M, Diaz-Rubio E, Casado A et al. Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol 1992; 10: 433-437.
21. O'Brien ME, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993; 11: 2112-2117.
22. Verschraegen CF, Kavanagh JJ, Loyer E et al. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer 2001; 92: 2327-2333.
23. Gonçalves A, Braud AC, Viret F et al. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors. Anticancer Res 2003; 23: 3543-3548.
24. Lê LH, Swenerton KD, Elit L et al. Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gynecol Cancer 2005; 15: 799-806.
25. Pignata S, Scambia G, Savarese A et al. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer 2006; 6: 202.
26. Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 2007; 18: 263-268.
27. Pignata S, Scambia G, Pisano C et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer 2007; 96: 1639-1643.
28. Power P, Stuart G, Oza A et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecol Oncol 2009; 114: 410-414.
29. Pignata S, Lauraine EP, du Bois A, Pisano C. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer. Critical Rev Oncol Hematol 2010; 73: 23-30.
30. Rapoport BL, Vorobiof DA, Slabber C et al. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer. Int J Gynecol Cancer 2009; 19: 1137-1141.
31. Weber B, Lortholary A, Mayer F et al. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res 2009; 29: 4195-4200.
32. Bafaloukos D, Linardou H, Aravantinos G et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med 2010; 8: 3.
33. Markman M, Moon J, Wilczynski S et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 2010; 116: 323-325.
34. nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat 2009; 117: 599-601.
35. Venturini M, Bighin C, Puglisi F et al. A multicentre Phase II study of nonpegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast 2010; 19: 333-338.